Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of IBI351 in Chinese Patients With KRAS G12C-Mutant Advanced NSCLC: A Retrospective Real-World Study

NCT07198620 is registered in ClinicalTrials.gov with Guangdong Association of Clinical Trials as lead sponsor.

NCT NCT07198620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07198620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of IBI351 in Chinese Patients With KRAS G12C-Mutant Advanced NSCLC: A Retrospective Real-World Study
Lead sponsor
Guangdong Association of Clinical Trials
Phase
Observational
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
December 1, 2026
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer (nsclc)